PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Clinical trials for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT explained in plain language.
Never miss a new study
Get alerted when new PROSTATIC NEOPLASMS, CASTRATION-RESISTANT trials appear
Sign up with your email to follow new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising theranostic approach targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new approach that combines imaging and treatment for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses a radioactive substance that targets a protein (PSMA) found on cancer cells. The goal is to see if it is safe a…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Disease control
Last updated May 17, 2026 04:30 UTC
-
New hope for tough prostate cancer: experimental drug combo under study
Disease control Recruiting nowThis study tests an experimental drug called MK-5684 (opevesostat), alone or with other treatments, for men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. About 220 participants will join to see if the drug is safe and can shrink tumo…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for tough prostate cancer? drug combo trial launches
Disease control Recruiting nowThis early-stage trial tests whether adding an experimental drug (TVB-2640) to the standard drug enzalutamide is safe for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 30 men will take part. The main goal is to find the best do…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for tough prostate cancer: drug combo aims to delay progression
Disease control Recruiting nowThis study tests whether adding pasritamig (a drug that helps the immune system attack cancer cells) to standard chemotherapy (docetaxel) can delay cancer growth in men with metastatic castration-resistant prostate cancer. About 800 men whose cancer has spread and is no longer co…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New drug cocktail aims to stall Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new two-drug combination (gedatolisib plus darolutamide) in men with metastatic castration-resistant prostate cancer, a type that has spread and stopped responding to standard hormone therapy. The goal is to find the safest, most effective dose and see if the c…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated May 12, 2026 13:43 UTC